A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer

Oncogene

Volumn 23, Issue 8, 2004, Pages 1636-1644

  Chien, Jeremy ^a   Staub, Julie ^a   Hu, Shou Ih ^b   Erickson Johnson, Michele R ^a   Couch, Fergus J ^a   Smith, David I ^a   Crowl, Robert M ^b   Kaufmann, Scott H ^c   Shridhar, Viji ^a,c  

^a MAYO CLINIC CANCER CENTER   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c MAYO CLINIC   (United States)

Author keywords

Downregulation; HtrA; Loss of heterozygosity; Ovarian cancer; Serine protease

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE INHIBITOR; PROTEIN HTRA1; SERINE PROTEINASE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; HIGH TEMPERATURE REQUIREMENT FACTOR A1, HUMAN; HIGH-TEMPERATURE REQUIREMENT FACTOR A1, HUMAN; MICROSATELLITE DNA;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CHROMOSOME 10Q; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE LOCUS; GENETIC TRANSFECTION; HTRA1 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROSATELLITE MARKER; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; APOPTOSIS; CELL ADHESION; CHROMOSOME 10; GENETIC MARKER; GENETICS; HETEROZYGOSITY LOSS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; OVARY TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

FALLOPIA;

APOPTOSIS; CELL ADHESION; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMOSOMES, HUMAN, PAIR 10; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GENETIC MARKERS; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERINE ENDOPEPTIDASES;

EID: 1542742098     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1207271     Document Type: Article

References (32)

1. Albarosa R, Colombo BM, Roz L, Magnani I, Polio B, Cirenei N, Giani C, Conti AM, DiDonato S and Finocchiaro G. (1996). Am. J. Hum. Genet., 58, 1260-1267.
2. Baldi A, De Luca A, Morini M, Battista T, Felsani A, Baldi F, Catricala C, Amantea A, Noonan DM, Albini A, Natali PG, Lombardi D and Paggi MG. (2002). Oncogene, 21, 6684-6688.
3. Clausen T, Southan C and Ehrmann M. (2002). Mol. Cell, 10, 443-455.
4. Conover CA, Hartmann LC, Bradley S, Stalboerger P, Klee GG, Kalli KR and Jenkins RB. (1998). Exp. Cell Res., 238, 439-449.
5. Deichmann M, Mollenhauer J, Helmke B, Thome M, Hartschuh W, Poustka A and Naher H. (2002). Oncology, 63, 166-172.
6. Enomoto T, Weghorst CM, Inoue M, Tanizawa O and Rice JM. (1991). Am. J. Pathol., 139, 777-785.
7. Garcia-Calvo M, Peterson EP, Leiting B, Ruel R, Nicholson DW and Thornberry NA. (1998). J. Biol. Chem., 273, 32608-32613.
8. Greenlee RT, Murray T, Bolden S and Wingo PA. (2000). CA Cancer J. Clin., 50, 7-33.
9. Hegde R, Srinivasula SM, Zhang Z, Wassell R, Mukattash R, Cilenti L, DuBois G, Lazebnik Y, Zervos AS, Fernandes-Alnemri T and Alnemri ES. (2002). J. Biol. Chem., 277, 432-438.
10. Hu SI, Carozza M, Klein M, Nantermet P, Luk D and Crowl RM. (1998). J. Biol. Chem., 273, 34406-34412.
11. Kato MV. (2000). Mol. Med., 6, 126-135.
12. Katsaros D, Theillet C, Zola P, Louason G, Sanfilippo B, Isaia E, Arisio R, Giardina G and Sismondi P. (1995). Anticancer Res., 15, 1501-1510.
13. Kohler MF, Marks JR, Wiseman RW, Jacobs IJ, Davidoff AM, Clarke-Pearson DL, Soper JT, Bast Jr RC and Berchuck A. (1993). J. Natl. Cancer Inst., 85, 1513-1519.
14. Krojer T, Garrido-Franco M, Huber R, Ehrmann M and Clausen T. (2002). Nature, 416, 455-459.
15. Li SB, Schwartz PE, Lee WH and Yang-Feng TL. (1991). J. Natl. Cancer Inst., 83, 637-640.
16. Martins LM, Iaccarino I, Tenev T, Gschmeissner S, Totty NF, Lemoine NR, Savopoulos J, Gray CW, Creasy CL, Dingwall C and Downward J. (2002). J. Biol. Chem., 277, 439-444.
17. Mollenhauer J, Wiemann S, Scheurlen W, Korn B, Hayashi Y, Wilgenbus KK, von Deimling A and Poustka A. (1997). Nat. Genet., 17, 32-39.
18. Mueller W, Mollenhauer J, Stockhammer F, Poustka A and von Deimling A. (2002). Oncogene, 21, 5956-5959.
19. Nie GY, Hampton A, Li Y, Findlay JK and Salamonsen LA. (2003). Biochem. J., 371 (Part 1), 39-48.
20. Orsulic S, Li Y, Soslow RA, Vitale-Cross LA, Gutkind JS and Varmus HE. (2002). Cancer Cell, 1, 53-62.
21. Ross JS, Yang F, Kallakury BV, Sheehan CE, Ambros RA and Muraca PJ. (1999). Am. J. Clin. Pathol., 111, 311-316.
22. Sasaki H, Betensky RA, Cairncross JG and Louis DN. (2002). Cancer Res., 62, 1790-1796.
23. Schwartz DI, Lindor NM, Walsh-Vockley C, Roche PC, Mai M, Smith DI, Liu W and Couch FJ. (1999). Breast Cancer Res. Treat., 58, 25-29.
24. Shridhar V, Sen A, Chien J, Staub J, Avula R, Kovats S, Lee J, Lillie J and Smith DI. (2002). Cancer Res., 62, 262-270.
25. Spiess C, Beil A and Ehrmann M. (1999). Cell, 97, 339-347.
26. Suzuki Y, Imai Y, Nakayama H, Takahashi K, Takio K and Takahashi R. (2001). Mol. Cell, 8, 613-621.
27. Swisshelm K, Ryan K, Tsuchiya K and Sager R. (1995). Proc. Natl. Acad. Sci. USA, 92, 4472-4476.
28. van den Hoff MJ, Moorman AF and Lamers WH. (1992). Nucleic Acids Res., 20, 2902.
29. Verhagen AM, Silke J, Ekert PG, Pakusch M, Kaufmann H, Connolly LM, Day CL, Tikoo A, Burke R, Wrobel C, Moritz RL, Simpson RJ and Vaux DL. (2002). J. Biol. Chem., 277, 445-454.
30. Williams MS and Henkart PA. (1994). J. Immunol., 153, 4247-4255.
31. Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, Cuevas B, Kuo WL, Gray JW, Siciliano M, Mills GB and Bast Jr RC. (1999). Proc. Natl. Acad. Sci. USA, 96, 214-219.
32. Zumbrunn J and Trueb B. (1996). FEBS Lett., 398, 187-192.